A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

Meningococcal Vaccine Clinical Trial

Official title:
A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered In Either 2- Or 3-dose Regimens In Healthy Subjects Aged Greater Than Or Equal To 11 To <19 Years

Status Completed

Clinical Trial Summary

This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how well it is tolerated. This study will also look at this vaccine being given 2 or 3 times. This study will be done in healthy adolescents.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Meningococcal Vaccine

Clinical Trial Details

NCT number	NCT01299480
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 2
Start date	March 3, 2011
Completion date	September 18, 2012

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04645966` - A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants	Phase 2
Completed	`NCT01323270` - A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.	Phase 2
Completed	`NCT04440176` - A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules	Phase 2
Completed	`NCT04440163` - MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age	Phase 3
Completed	`NCT03509051` - Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation	N/A
Completed	`NCT02975596` - MenB Vaccine: Implementation Via Information, Empowerment and Accessibility	N/A
Completed	`NCT03263403` - Non Inferiority Trial of Locally Manufactured Meningococcal ACWY Vaccine 'Ingovax ACWY' in Bangladesh.	Phase 2/Phase 3
Completed	`NCT04893811` - Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age	Phase 4
Completed	`NCT04819113` - Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age	Phase 3
Completed	`NCT03135834` - A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.	Phase 3
Completed	`NCT01830855` - A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years	Phase 3